Key facts
- This page summarizes Donald Joseph's Form 4 filing for Acer Therapeutics Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Nov 2023, 17:05.
Donald Joseph - 17 Nov 2023 Form 4 Insider Report for Acer Therapeutics Inc.
- Reporting relationship
- CHIEF LEGAL OFFICER AND SECRETARY
- Issuer ticker
- N/A
- Reported as of
- 17 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Nov 2023, 17:05:15 UTC
- Prior SEC filing
- 16 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Harry S. Palmin, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Donald Joseph filed Form 4 for Acer Therapeutics Inc. on 20 Nov 2023.
Change
- Previous filing in this sequence was filed on 16 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACER
transaction
Common Stock, $0.0001 par value per share
Disposed to Issuer
- Transaction value
- Shares
- -14,285
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 17 Nov 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Donald Joseph is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra.
Footnote F2
Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company.
Footnote F3
(Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34.
SEC remarks
CHIEF LEGAL OFFICER AND SECRETARY